Highlights
- •Adjuvant systemic treatment with sunitinib for patients with renal cell carcinoma (RCC) is controversial
- •Systemic adjuvant treatment with Sunitinib improves disease-free survival, however with considerable toxicity
- •Adjuvant systemic treatment with immune checkpoint inhibitors (ICI) is associated with lower risk of toxicity, however with conflicting clinical benefit
- •This meta-analysis, with the available high-level data of adjuvant systemic treatment with ICI for RCC patients, was not able to demonstrate survival benefit in the overall population.
Abstract
Background
Methods
Results
Conclusion
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerReferences
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021; 71: 209-249
- A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome.Eur Urol Focus. 2022; 8: 200-209
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.Cancer Treat Rev. 2021; 97102207
- Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience.J Urol. 2015; 193: 1911-1916
- Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.Clin Genitourin Cancer. 2018; 16: 176-183
- EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).Journal of Clinical Oncology. 2022; 40 (-LBA4500): LBA4500
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.N Engl J Med. 2016; 375: 2246-2254
- Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.Ther Adv Med Oncol. 2022; 1417588359221108685
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.New England Journal of Medicine. 2015; 373: 1803-1813
- Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.Cancer. 2022; 128: 2085-2097
- Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.Journal of Clinical Oncology. 2021; 39 (-327): 327
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.New England Journal of Medicine. 2021; 385: 683-694
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet Oncology. 2022; 23: 1133-1144
- Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.Journal of Clinical Oncology. 2022; 40 (-290): 290
- Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.The Lancet. 2022;
- LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial.Annals of Oncology. 2022; 33: S1432-S1433
- LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial.Annals of Oncology. 2022; 33: S1430
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ. 2021; 372: n71
- The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration.Systematic Reviews. 2013; 2: 79
- Cochrane hand-book for systematic reviews of interventions.2nd ed. Jonh Wiley & Sons, Chichester (UK)2019
NCCN Guidelines Kidney Cancer. 2023 [cited 2023 01/02/2023]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
- Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.Eur Urol Oncol. 2022; 5: 120-124
- Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.Cancer J. 2009; 15: 421-425
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.J Clin Oncol. 2017; 35: 3097-3104
- The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.JAMA Intern Med. 2015; 175: 1389-1398
- Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Cancer. 2018; 124: 925-933
- Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.Journal of Clinical Oncology. 2021; 39 (-4581): 4581
US Food & Drug Administration. Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment. 2022 [cited 2023 January 06, 2023]; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment.
- Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.Mol Immunol. 2020; 124: 35-41
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol. 2001; 2: 261-268
- Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.Front Immunol. 2020; 11: 1088
- Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.Sci Rep. 2019; 9: 11472
- Anti-drug antibodies in the current management of cancer.Cancer Chemotherapy and Pharmacology. 2022; 89: 577-584
- Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?.Clin Cancer Res. 2020; 26: 787-792
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2020; 6: 375-384
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.Ann Oncol. 2020; 31: 1030-1039
- Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.JAMA Oncol. 2022; 8: 275-280
- Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).Journal of Clinical Oncology. 2021; 39 (-4576): 4576
- Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).J Clin Oncol. 2020; 38: 4240-4248
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.Journal of Clinical Oncology. 2022; 40 (-288): 288
- Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.J Clin Oncol. 2021; 39: 1029-1039
- Placebo effect studies are susceptible to response bias and to other types of biases.J Clin Epidemiol. 2011; 64: 1223-1229
- Informative censoring of surrogate end-point data in phase 3 oncology trials.Eur J Cancer. 2021; 153: 190-202
- Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.Cancer. 2022; 128: 2892-2897
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.J Immunother Cancer. 2018; 6: 9
- Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.J Immunother Cancer. 2022; 10
- Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.Clin Genitourin Cancer. 2020; 18: 429-435
- Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium.European Urology Oncology. 2020; 3: 530-539
- Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.European Urology. 2018; 74: 611-620
- Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.Clinical Genitourinary Cancer. 2019; 17: e339-e344
- Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.Urologic Oncology: Seminars and Original Investigations. 2021; 39: 764-773
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun. 2021; 12: 808
- First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.Cancer Treat Rev. 2022; 105102374
- Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.Current Opinion in Urology. 2022; 32: 61-68
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.ESMO Open. 2020; 5e001079
- LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313).Annals of Oncology. 2022; 33: S1430-S1431
- Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.Oncologist. 2022;
- A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).Journal of Clinical Oncology. 2020; 38 (-TPS5099): TPS5099
- RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.Contemp Clin Trials. 2021; 108106482
- ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.Annals of Oncology. 2021; 32: 1511-1519
- LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).Journal of Clinical Oncology. 2022; 40 (-TPS4602): TPS4602
- Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.Clin Cancer Res. 2018; 24: 4407-4415
- Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma.Eur Urol Oncol. 2022;